- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05344404
NR-SAFE: Safety of High-dose Nicotinamide Riboside (NR) in Parkinson's Disease (NR-SAFE)
NR-SAFE: a Safety Study Investigating Treatment With High-dose Nicotinamide Riboside (NR) in Parkinson's Disease
NR-SAFE is a double-blinded randomized safety study aiming to determine the safety and tolerability of nicotinamide riboside (NR) at a daily dose of 3000mg, in individuals with Parkinson's disease (PD).
The investigators recently reported the results of the NADPARK study (ClinicalTrials.gov: NCT03816020), a phase I randomized, double-blinded trial, assessing the tolerability, cerebral bioavailability and molecular effects of NR therapy, 1000mg daily, in PD. The NADPARK study showed that NR 1000mg daily was well tolerated and led to a significant, but variable, increase in cerebral NAD levels (measured by 31phosphorous magnetic resonance spectroscopy, 31P-MRS) and related metabolites in the cerebrospinal fluid (CSF). NR recipients showing increased brain NAD levels exhibited altered cerebral metabolism, measured by 18fluoro-deoxyglucose positron emission tomography (FDG-PET), and this was associated with mild clinical improvement. The results of the NADPARK trial nominate NR as a potential neuroprotective therapy for PD, warranting further investigation in larger trials.
It is plausible that any beneficial effects of NR in PD may be dose-dependent and more pronounced at higher doses. NR doses of up to 2000mg daily have been tested in healthy humans with no signs of toxicity. However, the safety and tolerability of even higher doses is untested. To enable clinical studies assessing higher doses, the investigators will assess the safety and tolerability of an oral dose of 3000 mg NR daily.
NR-SAFE will recruit 20 participants with PD and randomize them 1:1 to either NR 3000mg daily or placebo for a total duration of 4 weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
NR-SAFE is a double-blinded randomized safety study aiming to determine the safety and tolerability of nicotinamide riboside (NR) at a daily dose of 3000mg, in individuals with Parkinson's disease (PD). Individuals with PD (n = 20) will be recruited starting April 2022. Participants will be randomized 1:1 to either NR 3000mg daily (1500mg x 2) or placebo per os for a total duration of 4 week. Both the participants and the investigators will be blinded.
Primary Objective:
To determine the safety of oral NR 3000mg daily for a period of 4 weeks in individuals with Parkinson's disease (PD). Safety is defined as the absence of clinically significant NR-associated moderate or severe adverse events (AE).
Secondary Objectives:
- Determine whether oral NR 3000 mg daily is associated with mild AE.
- Assess the effects of oral NR 3000 mg daily on the NAD metabolome in blood and urine.
- Assess the effects of oral NR 3000 mg daily on clinical severity of PD, measured by UPDRS.
Exploratory Objectives:
- Assess the effects of oral NR 3000 mg daily on serum homocysteine levels.
- Assess the effects of oral NR 3000 mg daily on fasting blood glucose and serum insulin levels.
Procedures:
After the baseline visit, participants will be reassessed in person on day 5, 7, 14, 21 and 28 by one of the neurologists involved in the study and by telephone on day 3 and 35 by the study nurse. Participants will be screened for any adverse effects on each of these consultations. Drawing of blood samples will be performed on baseline and day 3, 5, 7, 14, 21 and 28. Clinical examination and measurement of vital parameters will be performed on baseline and on day 7, 14, 21 and 28.
Primary Outcome:
Incidence of treatment-associated moderate and severe AEs.
Secondary Outcomes:
- Between-group difference in treatment associated mild AEs.
- Between-group difference in changes of the NAD metabolome in blood and urine, measured by mass spectrometry (LC-MS/MS Q-Exactive HF).
- Between-group difference in change of clinical severity of PD, measured by UPDRS.
Exploratory Outcomes:
- Between-group difference in the change of serum homocysteine levels.
- Between-group difference in the change of fasting blood glucose and serum insulin levels.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bergen, Norway
- Haukeland University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age equal to or greater than 35 years and lower than 100 years at time of enrollment.
- Clinical diagnosis of idiopathic PD according to the MDS criteria.
- Hoehn and Yahr score < 4 at enrolment.
Exclusion Criteria:
- Dementia or other neurodegenerative disorder at baseline visit.
- Any psychiatric disorder that would interfere with compliance in the study.
- Any severe somatic illness that would make the individual unable to comply and participate in the study.
- Use of high dose vitamin B3 supplementation within 30 days of enrollment.
- Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nicotinamide Riboside
Nicotinamide riboside 3000mg daily for the duration of the trial (4 weeks).
Administered in tablet form in doses of 1500mg twice daily.
|
3000mg total daily.
Administered in capsule form in doses of 1500mg twice daily for the duration of the trial (4 weeks).
Other Names:
|
Placebo Comparator: Placebo
Placebo, no active ingredients.
Administered in tablet form twice daily for the duration of the trial (4 weeks).
|
Placebo drug.
Administered in tablet form twice daily for the duration of the trial (4 weeks).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-associated moderate and severe adverse events (AEs).
Time Frame: 4 weeks.
|
The incidence of treatment-associated moderate and severe adverse events (AEs) will be assessed.
|
4 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-associated mild adverse events (AEs).
Time Frame: 4 weeks.
|
The incidence of treatment-associated mild adverse events (AEs) will be assessed.
|
4 weeks.
|
Between-group (NR vs placebo) difference in changes of the NAD metabolome in blood and urine, measured by mass spectrometry (LC-MS/MS Q-Exactive HF)
Time Frame: 4 weeks.
|
The concentration of NAD metabolites, such as NAD, NAAD, NAM, meNAM, etc, will be determined in blood (snap-frozen EDTA) and urin using liquid chromatography mass spectrometry (LC-MS/MS Q-Exactive HF).
The change in the concentration of NAD metabolites in the NR and placebo group, as well as the between-group (NR vs placebo) difference in the change of the concentration of NAD metabolites will be assessed.
|
4 weeks.
|
Between-group (NR vs placebo) difference in change of clinical severity of PD, measured by UPDRS.
Time Frame: 4 weeks.
|
The change in total UPDRS in the NR and placebo group, as well as the between-group (NR vs placebo) difference in the change of total UPDRS will be assessed.
|
4 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charalampos Tzoulis, MD, PhD, Haukeland University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Antimetabolites
- Micronutrients
- Hypolipidemic Agents
- Lipid Regulating Agents
- Vitamins
- Vitamin B Complex
- Nicotinic Acids
- Niacinamide
- Niacin
Other Study ID Numbers
- 2021/379218
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Nicotinamide Riboside
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridge; Medical Research Council Mitochondrial Biology UnitCompletedMitochondrial Diseases | Mitochondrial Myopathies | Progressive External Ophthalmoplegia | Progressive Ophthalmoplegia | Progressive; Ophthalmoplegia, External | Mitochondria DNA Deletion | MELASUnited Kingdom
-
National Heart, Lung, and Blood Institute (NHLBI)TerminatedHeart FailureUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedObesity | Psoriasis | Dyslipidemia | Atherosclerotic Cardiovascular Disease | Cardiometabolic DiseasesUnited States
-
Iowa State UniversityCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCancer | Muscle Weakness | Skin FibroblastsUnited States
-
Haukeland University HospitalHaraldsplass Deaconess HospitalRecruitingDementia | Alzheimer DiseaseNorway
-
ChromaDex, Inc.Midwest Center for Metabolic and Cardiovascular ResearchCompletedSleep | Cognitive Function | MoodUnited States
-
Société des Produits Nestlé (SPN)Active, not recruiting
-
MediGeneCharité Research Organisation GmbHCompletedGenital Warts | Perianal WartsGermany
-
Haukeland University HospitalRecruiting